Albert Kim

Uncovering the mechanisms driving the rebound phenomenon following denosumab discontinuation🦴 Excited to share our work showing an earlier 'window of opportunity' for sequential therapy bit.ly/3PRKgz1 via @The_JBMR @michbal19 @ArielCM14 @GarvanInstitute

Thank you Dr. Kim @AlbertEndoc for your discussion of the mechanisms driving rebound #bone loss following denosumab discontinuation, from the April issue! youtu.be/sDSFt6P0Vrk?si… @ASBMR @OUPMedicine @michbal19 @ArielCM14 @GarvanInstitute

Thank you to the generous support by @EndoSocAus and Korean Endocrine Society to allow me to attend and present at #SICEM2024 on behalf of our wonderful team @michbal19 @ArielCM14

Encouraged to see that the Korean Endocrine Society has a dedicated Committee of the Future Endocrinologist Sustainability (headed by Dr Jeonghoon Ha) who were keen to continue sharing ideas and strategies to potentially implement locally with @EndoSocAus

Common barriers and challenges in promoting endocrinology to the next generation across Korea, Australia, Singapore and the US, including the need for better 'branding', improving remuneration:workload and better support throughout training.

Thank you to #SICEM2024 for a dedicated session focussing on the challenges facing early career clinicians and researchers. Australian perspective presented by @NatalieASims with @EndoSocAus @ANZBMSoc input

Very excited to be attending and presenting at #SICEM2024

@DrJenLi_Renal Thanks Jen! 🙇

Great work @AlbertEndoc 💪

A massive THANK YOU to all our friends, colleagues, collaborators and funding bodies that support our work, and without whom this work would not have been possible! This study is opens up opportunities to explore our exciting hypotheses - stay tuned!

Overall, we show that the drivers of the rebound phenomenon are in play before BMD loss is detectable. Waiting for BMD loss or CTX rise is likely too late to intervene to stop this process! A rise in TRAP occurs earlier and this may be a better marker in this context!

Denosumab is a great medication to treat osteoporosis and prevent fractures but stopping treatment leads to a rebound loss in bone and increased risk of fractures. Current strategies to prevent this have not worked and we used our mouse model to show why:

Uncovering the mechanisms driving the rebound phenomenon following denosumab discontinuation🦴 Excited to share our work showing an earlier 'window of opportunity' for sequential therapy bit.ly/3PRKgz1 via @The_JBMR @michbal19 @ArielCM14 @GarvanInstitute

Our case of #SGLT2 inhibitor associated ketoacidosis in a patient without diabetes. These medications have so many benefits 🫀🫘🏥 but pharmacovigilance is also important @SVHSydney @GarvanInstitute @VictorChangInst

Less than a week to go until #ESASRB23 - we can’t wait to see you there! Last chance to register!

Pro-osteoclastogenic environment is in place before rebound bone loss is clinically detectable by serum bone turnover markers - nice talk by @michbal19 #ANZBMS2023 @ANZBMS_ECIC @ANZBMSoc